Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

Inclusion Criteria: * Diagnosis of RA \< 5 years * Functional class I, II, or II as defined by the American College of Rheumatology (ACR) criteria. * Must have failed at least 1 Disease Modifying Anit-Rheumatic Drug (DMARD) * Joint count of 10 or more swollen and 12 or more tender. * Erythrocyte Sedimentation Rate (ESR) \> - 28mm/rr or norning stiffness \> - 45 minutes. Exclusion Criteria: * Women and men who are not willing to use an accepted form of contraception. * Active vasculitis * Treatment with another investigational drug within 30 days * History of asthma, angioedema, or anaphylaxix